tiprankstipranks
Keros Therapeutics, Inc. (KROS)
NASDAQ:KROS
US Market
KROS
Keros Therapeutics
RESEARCH TOOLSreports
Want to see KROS full AI Analyst Report?

Keros Therapeutics (KROS) Stock Forecast & Price Target

365 Followers
See the Price Targets and Ratings of:

KROS Analyst Ratings

Moderate Buy
8Ratings
Moderate Buy
5 Buy
3 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Keros
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

KROS Stock 12 Month Forecast

Average Price Target

$21.20
▲(81.66% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Keros Therapeutics in the last 3 months. The average price target is $21.20 with a high forecast of $30.00 and a low forecast of $16.00. The average price target represents a 81.66% change from the last price of $11.67.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","31":"$31","15.25":"$15.25","20.5":"$20.5","25.75":"$25.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,15.25,20.5,25.75,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.49,12.913846153846155,14.337692307692308,15.76153846153846,17.185384615384613,18.60923076923077,20.033076923076923,21.456923076923076,22.880769230769232,24.30461538461538,25.728461538461538,27.152307692307694,28.576153846153844,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.49,12.236923076923077,12.983846153846153,13.73076923076923,14.477692307692308,15.224615384615383,15.971538461538461,16.71846153846154,17.465384615384615,18.21230769230769,18.959230769230768,19.706153846153846,20.45307692307692,{"y":21.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.49,11.836923076923076,12.183846153846154,12.53076923076923,12.877692307692307,13.224615384615385,13.571538461538461,13.918461538461539,14.265384615384615,14.612307692307692,14.95923076923077,15.306153846153846,15.653076923076924,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.57,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.34,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.72,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.28,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.22,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.18,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.36,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.91,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.69,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.49,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$30.00Average Price Target$21.20Lowest Price Target$16.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wedbush Analyst forecast on KROS
Yun Zhong
Wedbush
Wedbush
$16
Hold
37.10%
Upside
Reiterated
05/19/26
Hold Rating Reiterated on Keros as Takeda Partnership Progress Offsets Rinvatercept Delays; $16 Price Target Maintained
H.C. Wainwright Analyst forecast on KROS
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
$20
Buy
71.38%
Upside
Reiterated
05/15/26
Keros Therapeutics: Buy Rating Reaffirmed on Rinvatercept-Focused Strategy and Unchanged $20 Price Target
Truist Financial Analyst forecast on KROS
Srikripa Devarakonda
Truist Financial
Truist Financial
―
Buy
―
Reiterated
05/15/26
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (NASDAQ: KROS), Cormedix (NASDAQ: CRMD) and Biogen (NASDAQ: BIIB)
Wells Fargo Analyst forecast on KROS
Benjamin Burnett
Wells Fargo
Wells Fargo
$20
Buy
71.38%
Upside
Reiterated
05/15/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: RegenXBio (NASDAQ: RGNX), Align Tech (NASDAQ: ALGN) and Keros Therapeutics (NASDAQ: KROS)
William Blair Analyst forecast on KROS
Matt Phipps
William Blair
William Blair
―
Hold
―
Reiterated
05/14/26
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (NASDAQ: KROS) and Pelthos Therapeutics (NYSE MKT: PTHS)
TD Cowen Analyst forecast on KROS
Nicholas Lorusso
TD Cowen
TD Cowen
―
Hold
―
Reiterated
05/14/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Keros Therapeutics (NASDAQ: KROS), Jasper Therapeutics (NASDAQ: JSPR) and Corvus Pharmaceuticals (NASDAQ: CRVS)
Leerink Partners Analyst forecast on KROS
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
$30
Buy
157.07%
Upside
Reiterated
03/06/26
Keros Therapeutics (KROS) Receives a Buy from Leerink Partners
Raymond James Analyst forecast on KROS
Tiago Fauth
Raymond James
Raymond James
$23→$20
Buy
71.38%
Upside
Reiterated
03/05/26
Keros Therapeutics price target lowered to $20 from $23 at Wells FargoKeros Therapeutics price target lowered to $20 from $23 at Wells Fargo
Bank of America Securities Analyst forecast on KROS
Jason Zemansky
Bank of America Securities
Bank of America Securities
$19→$20
Hold
71.38%
Upside
Reiterated
01/05/26
Bank of America Securities Keeps Their Hold Rating on Keros Therapeutics (KROS)
Scotiabank Analyst forecast on KROS
Greg Harrison
Scotiabank
Scotiabank
$26
Buy
122.79%
Upside
Reiterated
06/10/25
Keros Therapeutics (KROS) Receives a Buy from Scotiabank
Guggenheim Analyst forecast on KROS
Vamil Divan
Guggenheim
Guggenheim
―
Hold
―
Reiterated
05/29/25
Guggenheim Sticks to Their Hold Rating for Keros Therapeutics (KROS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wedbush Analyst forecast on KROS
Yun Zhong
Wedbush
Wedbush
$16
Hold
37.10%
Upside
Reiterated
05/19/26
Hold Rating Reiterated on Keros as Takeda Partnership Progress Offsets Rinvatercept Delays; $16 Price Target Maintained
H.C. Wainwright Analyst forecast on KROS
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
$20
Buy
71.38%
Upside
Reiterated
05/15/26
Keros Therapeutics: Buy Rating Reaffirmed on Rinvatercept-Focused Strategy and Unchanged $20 Price Target
Truist Financial Analyst forecast on KROS
Srikripa Devarakonda
Truist Financial
Truist Financial
―
Buy
―
Reiterated
05/15/26
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (NASDAQ: KROS), Cormedix (NASDAQ: CRMD) and Biogen (NASDAQ: BIIB)
Wells Fargo Analyst forecast on KROS
Benjamin Burnett
Wells Fargo
Wells Fargo
$20
Buy
71.38%
Upside
Reiterated
05/15/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: RegenXBio (NASDAQ: RGNX), Align Tech (NASDAQ: ALGN) and Keros Therapeutics (NASDAQ: KROS)
William Blair Analyst forecast on KROS
Matt Phipps
William Blair
William Blair
―
Hold
―
Reiterated
05/14/26
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (NASDAQ: KROS) and Pelthos Therapeutics (NYSE MKT: PTHS)
TD Cowen Analyst forecast on KROS
Nicholas Lorusso
TD Cowen
TD Cowen
―
Hold
―
Reiterated
05/14/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Keros Therapeutics (NASDAQ: KROS), Jasper Therapeutics (NASDAQ: JSPR) and Corvus Pharmaceuticals (NASDAQ: CRVS)
Leerink Partners Analyst forecast on KROS
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
$30
Buy
157.07%
Upside
Reiterated
03/06/26
Keros Therapeutics (KROS) Receives a Buy from Leerink Partners
Raymond James Analyst forecast on KROS
Tiago Fauth
Raymond James
Raymond James
$23→$20
Buy
71.38%
Upside
Reiterated
03/05/26
Keros Therapeutics price target lowered to $20 from $23 at Wells FargoKeros Therapeutics price target lowered to $20 from $23 at Wells Fargo
Bank of America Securities Analyst forecast on KROS
Jason Zemansky
Bank of America Securities
Bank of America Securities
$19→$20
Hold
71.38%
Upside
Reiterated
01/05/26
Bank of America Securities Keeps Their Hold Rating on Keros Therapeutics (KROS)
Scotiabank Analyst forecast on KROS
Greg Harrison
Scotiabank
Scotiabank
$26
Buy
122.79%
Upside
Reiterated
06/10/25
Keros Therapeutics (KROS) Receives a Buy from Scotiabank
Guggenheim Analyst forecast on KROS
Vamil Divan
Guggenheim
Guggenheim
―
Hold
―
Reiterated
05/29/25
Guggenheim Sticks to Their Hold Rating for Keros Therapeutics (KROS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Keros Therapeutics

3 Months
Thomas SmithLeerink Partners
Success Rate
16/26 ratings generated profit
62%
Average Return
+13.07%
Copying Thomas Smith's trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +13.07% per trade.
1 Year
Srikripa DevarakondaTruist Financial
Success Rate
8/18 ratings generated profit
44%
Average Return
-9.42%
Copying Srikripa Devarakonda's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -9.42% per trade.
2 Years
Thomas SmithLeerink Partners
Success Rate
5/26 ratings generated profit
19%
Average Return
-40.57%
Copying Thomas Smith's trades and holding each position for 2 Years would result in 19.23% of your transactions generating a profit, with an average return of -40.57% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KROS Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
2
0
6
6
8
Buy
3
1
1
1
2
Hold
5
1
4
3
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
2
11
10
17
In the current month, KROS has received 10 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. KROS average Analyst price target in the past 3 months is 21.20.
Each month's total comprises the sum of three months' worth of ratings.

KROS Financial Forecast

KROS Earnings Forecast

Next quarter’s earnings estimate for KROS is -$1.43 with a range of -$1.84 to -$1.20. The previous quarter’s EPS was -$1.21. KROS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year KROS has Performed in-line its overall industry.
Next quarter’s earnings estimate for KROS is -$1.43 with a range of -$1.84 to -$1.20. The previous quarter’s EPS was -$1.21. KROS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year KROS has Performed in-line its overall industry.

KROS Sales Forecast

Next quarter’s sales forecast for KROS is $807.00K with a range of $0.00 to $4.00M. The previous quarter’s sales results were $367.00K. KROS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year KROS has Performed in-line its overall industry.
Next quarter’s sales forecast for KROS is $807.00K with a range of $0.00 to $4.00M. The previous quarter’s sales results were $367.00K. KROS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year KROS has Performed in-line its overall industry.

KROS Stock Forecast FAQ

What is KROS’s average 12-month price target, according to analysts?
Based on analyst ratings, Keros Therapeutics, Inc.’s 12-month average price target is 21.20.
    What is KROS’s upside potential, based on the analysts’ average price target?
    Keros Therapeutics, Inc. has 81.66% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is KROS a Buy, Sell or Hold?
          Keros Therapeutics, Inc. has a consensus rating of Moderate Buy which is based on 5 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Keros Therapeutics, Inc.’s price target?
            The average price target for Keros Therapeutics, Inc. is 21.20. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $30.00 ,the lowest forecast is $16.00. The average price target represents 81.66% Increase from the current price of $11.67.
              What do analysts say about Keros Therapeutics, Inc.?
              Keros Therapeutics, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of KROS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.